Skip to content
WeighLab
Menu
Ranked #166 · Grade C

PlushCare review

PlushCare (a Transcarent, Inc. subsidiary) is a virtual primary-care platform whose board-certified MDs can prescribe brand-name GLP-1s (via insurance or Novo Nordisk's NovoCare cash-pay program) or compounded semaglutide/tirzepatide in a roughly 39-state footprint.

Visit PlushCare Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$199/mo (0.25 mg dose, plus a separate fee, brand-name)
Tirzepatide
$399/mo (5 mg dose, plus a separate fee, compounded)
Coverage
All 50 states
Brand-name
Yes

Semaglutide · modeled / year

$2,388

Tirzepatide · modeled / year

$4,788

Pricing verified August 2026

The Index scorecard

PlushCare scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month45/100
Price Transparency64/100
Nationwide Access86/100
Formulation Options79/100
Clinical Oversight82/100
Contract Flexibility41/100

Where the value is

  • Board-certified physicians (not NP-only) available in all 50 states for general virtual primary care
  • Publishes an unusually granular compounded-tirzepatide dose ladder ($399/$599/$749 by vial count) instead of a vague single 'starting at' figure
  • Brand Wegovy via NovoCare's manufacturer program can beat most compounded prices ($199-399/mo) when the promotion is genuinely still active
  • Owned by Transcarent, a venture-backed platform with a named, traceable corporate lineage
  • Insurer prior-authorization outreach and an in-app prescription discount card for patients who do have coverage

The tradeoffs

  • Compounded tirzepatide and semaglutide are each only available in about 39 states plus DC, narrower than PlushCare's general 50-state telehealth business
  • A $19.99/mo membership and, for uninsured patients, a $129 visit fee sit on top of every medication price and are easy to miss from the headline drug price alone
  • The advertised NovoCare Wegovy pricing is explicitly time-boxed by the manufacturer ('valid through March 2026' on the live page) — that date has already passed, so the checkout rate may differ from what's displayed
  • Facing a class-action settlement (Robbins v. PlushCare) alleging patients were enrolled in a recurring monthly subscription without clear disclosure or an easy cancellation path
  • GLP-1 prescribing is a clinician's in-visit judgment call, not guaranteed at signup

The bottom line

Best for: Patients who want a real board-certified physician managing GLP-1s alongside general primary care, and are prepared to navigate insurance or a manufacturer cash-pay program rather than a single flat price. PlushCare (a Transcarent, Inc. subsidiary) is a virtual primary-care platform whose board-certified MDs can prescribe brand-name GLP-1s (via insurance or Novo Nordisk's NovoCare cash-pay program) or compounded semaglutide/tirzepatide in a roughly 39-state footprint.

Ranked #166 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to PlushCare.

The 18 programs nearest this one

Pricing, states and verification reflect PlushCare's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on PlushCare's site. Not medical advice; see our disclosure.

← Back to the value leaderboard